Sarcoidosis lymphoma syndrome - the value of PET-CT in the diagnosis
© Kis et al.; licensee BioMed Central Ltd. 2013
Received: 7 November 2012
Accepted: 5 September 2013
Published: 18 September 2013
We report a 52-year-old patient who developed B-cell non-Hodgkin’s lymphoma subsequent to sarcoidosis. Sarcoidosis was diagnosed 16 years ago and remained asymptomatic for 14 years after steroid treatment. She presented with new symptoms of arthralgia, photosensitivity, butterfly erythema, autoimmune antibodies (ANA, chromatin positivity) associated with progression of the known left upper lobe lesion on the chest X-ray suggesting primary autoimmune disease (systemic lupus erythematosus). As steroid treatment was not effective, we started bolus cyclophosphamide therapy after which progression was seen on the chest X-ray. Computed tomography (CT)-guided needle biopsy confirmed malignancy of indefinable origin. Despite of the well-known fluorodeoxyglucose (FDG) avidity in active sarcoidosis, a FDG-positron emission tomography (PET) scan was performed to stage the primary tumour. Intensive FDG uptake was detected in the affected lung segment, with moderate uptake in mediastinal lymph nodes. The patient underwent left upper lobectomy. The histology showed pulmonary mucosa-associated lymphoma (bronchus-associated lymphoid tissue (BALT) lymphoma) in the lung tissue, while only sarcoidosis was present in the mediastinal lymph nodes. Bone marrow biopsy was negative.
The association between sarcoidosis and lymphoma is known as sarcoidosis lymphoma syndrome, which is a rare disease. PET-CT was helpful in the differentiation of sarcoidosis and malignancy in this patient. It is important to be aware of the risk of lymphoma in sarcoidosis and FDG-PET, used for adequate purpose, can help the diagnosis.
KeywordsSarcoidosis Malignancy Sarcoidosis lymphoma syndrome PET-CT
Bronchus associated lymphoid tissue
Mucosa associated lymphoid tissue
Positron emission tomography
Systemic lupus erythematosus.
Sarcoidosis is a chronic granulomatous inflammatory multisystem disorder of unknown origin. The association between sarcoidosis and malignancy - particularly lymphoproliferative disease, such as non-Hodgkin’s lymphoma - has been previously described [1–3]. In sarcoidosis lymphoma syndrome, sarcoidosis is followed by the development of the lymphoproliferative disorder . Higher fluorodeoxyglucose (FDG)-uptake may be seen in both diseases; therefore, positron emission tomography-computed tomography (PET-CT) cannot exclude or prove the presence of malignancy in sarcoidosis patients. In our case report of sarcoidosis lymphoma syndrome, we demonstrate how PET-CT could help within the decision making process.
Sarcoidosis is a multisystem granulomatous disorder of uncertain origin. The diagnosis of sarcoidosis is based on clinical, radiological, biochemical and histological findings. These findings are erythema nodosum, lymphopenia, hypergammaglobulinemia, anergy, hypercalcemia and elevated angiotensin-converting enzyme. The non-caseating granulomas are B-cell negative . The results should be carefully interpreted, because sarcoid-like granulomas can be found in many other disorders, such as chronic inflammatory, infectious and neoplastic diseases . Incidence is influenced by age, race and geographical location. The subacute form diagnosed in most patients under the age of 30 affects mainly intrathoracic organs and the duration of the disease is generally less than two years. The chronic form begins more often over the age of 40 and might involve extrathoracic organs .
Brincker and Wilbek have matched all patients who had been diagnosed with respiratory sarcoidosis during the period 1962 to 1971 against the data of the Cancer Registry. About 1.5 times higher incidence of cancer was seen in sarcoidosis patients. Lung cancer occurred 3 times and malignant lymphoma 11.5 times more frequently than in the control population . In a later study, Brincker found three features of malignancies following sarcoidosis based on the analysis of 29 case reports in the literature : the median age of the patients was 41 years at the diagnosis of sarcoidosis, which indicates a late onset, and is more often associated with a chronic type . Lymphoproliferative disease (LD) has occurred with a median interval of 24 months after the diagnosis of sarcoidosis . Hodgkin’s disease was diagnosed more frequently than other types of lymphomas. Further analysis of 17 cases revealed that LD developed 5.5 times more frequently than expected, which may suggest that the chronic active type of sarcoidosis is a predisposing factor for LD. Brincker introduced the term sarcoidosis lymphoma syndrome for this specific condition . In a retrospective cohort study Askling and his colleagues assessed the risk for malignancy in sarcoidosis. They linked a sarcoidosis incidence study (Uppsala Cohort) and patients identified with sarcoidosis in the Swedish Inpatient Register to population-based registers (Cancer Register, Register of Causes of Death, Register of Total Population). Significantly increased risk for malignant diseases including lung, stomach, small intestine and liver, for melanoma and non-melanoma skin cancer, non-Hodgkin’s lymphoma (NHL) and leukaemia was noted. For non-Hodgkin’s lymphoma the risk was nearly doubled five to nine years after the diagnosis of sarcoidosis .
There are many theories explaining the possible relationship of this association. The changes in the number and the functions of immune cells in sarcoidosis are well described, suggesting dysfunction in the immunoregulatory pathways leading to granuloma formation. A clone may escape in an environment with defective T suppressor cells regulation resulting in the development of lymphoid malignancy. In this context, chronic sarcoidosis represents a more prolonged and more severe form of the disease. Steroid treatment, by further compromising the immune system, might be an additional predisposing factor . There are some cases in which LD developed subsequent to sarcoidosis [6, 7], but only a few case reports present malignancy preceding sarcoidosis. Suen et al. described six patients who developed malignancy first, followed by the diagnosis of sarcoidosis. The median interval between the diagnoses of the two diseases was only nine months . There are also some patients with NHL, who developed sarcoidosis subsequent to the diagnosis of LD. Kornacker et al. reported two cases, where NHL was identified and treated for 3 and 10 months before the diagnosis of sarcoidosis. They proposed that sarcoidosis had been triggered by immunological disturbance induced by chemotherapy or associated with the lymphoma. They supposed an infectious agent, which could have spread due to the immunosuppression (caused by chemotherapy) resulting in granuloma formation. Alternatively antineoplastic therapy might have reduced suppressor T cells leading to lymphocyte activation observed in sarcoidosis . Sybert et al. reported a patient with osteosarcoma who developed granulomatous lymphadenopathy and multiple pulmonary nodules confirmed as sarcoidosis following cessation of treatment. They suggested that immunosuppression inhibited the development of sarcoidosis, which became symptomatic when chemotherapy was terminated .
FDG-PET is a sensitive method for the staging of several malignancies, the underlying biological principle is based on the Warburg effect . FDG is transported into cells by glucose transporter GLUT-1 and is metabolized to FDG-6-phosphate and trapped . The degree of the FDG uptake depends on the number of transporters and on the metabolic rate. Physiological activity is detected in the brain, myocardium and genitourinary tract. Due to increased metabolism, malignant tissues typically demonstrate higher FDG uptake than benign lesions and normal tissues. In patients with sarcoidosis, FDG-PET could be used for monitoring the response to treatment because FDG uptake correlates with disease activity but is not useful for initial diagnosis as it could be misinterpreted as a malignancy .
In a study with 21 patients, Bae et al. found that BALT lymphomas show heterogeneous but identifiable FDG uptake on PET scans . They analyzed the role of FDG-PET for staging and follow-up of patients with extranodal marginal zone mucosa (mucosa associated lymphoid tissue, MALT) lymphomas. A total of 42 patient scans and clinical information were reviewed. MALT lymphomas have high FDG avidity and PET scan is usable for detection of areas of transformation and for staging. In 34 of the 42 patients, there was FDG avidity, which demonstrated that FDG-PET scan is a possible diagnostic tool for the detection of MALT lymphoma in the majority of patients. Eleven patients who had BALT lymphoma in their lung all showed focal FDG uptake on PET scans. The authors suggested that with the advance and spread of the technology, its role in cancer - especially in MALT lymphomas - will expand and will lead to more accurate staging and better management of the disease .
According to the current literature, our patient had chronic sarcoidosis and had been treated with systemic steroids. The development of autoimmunity (SLE) and its treatment with cyclophosphamide induced changes in the slow growing tumour. This is in line with the theory that abnormal immune function contributes to the development of LD, and that immunosuppressive therapy may enhance it [16, 17]. The development of lymphoma presented over a decade.
According to previous observations, sarcoidosis predisposes for lymphoid malignancies. Sarcoidosis and lymphoma both can cause increased FDG uptake in mediastinal lymph nodes, thus FDG-PET-CT cannot prevent the need for histological verification . In our patient suffering from sarcoidosis, malignancy was only confirmed by cytology so FDG-PET-CT was an important diagnostic tool in the further decision-making process. The progression of the lung lesion, later confirmed as BALT lymphoma, occured following steroid and cyclophosphamide treatment (both agents used in the treatment of lymphomas), which was retrospectively interesting and unexpected. Future studies are needed to assess the full potential of FDG-PET-CT in the diagnosis of sarcoidosis lymphoma syndrome.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This work is in memory of Pal Magyar, who helped the authors with writing this article.
- Brincker H: Interpretation of granulomatous lesions in malignancy. Acta Oncol 1992, 31:85–89.PubMedView Article
- Karakantza M, Matutes E, MacLennan K, O'Connor NT, Srivastava PC, Catovsky D: Association between sarcoidosis and lymphoma revisited. J Clin Pathol 1996, 49:208–212.PubMedView Article
- Brincker H, Wilbek E: The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer 1974, 29:247–252.PubMedView Article
- Brincker H: The sarcoidosis-lymphoma syndrome. Br J Cancer 1986, 54:467–473.PubMedView Article
- Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A: Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999, 160:1668–1672.PubMedView Article
- Oliwiecki S, Kotecha B, Kingston T, Rothera MP: Sarcoidosis-lymphoma syndrome. J R Soc Med 1992, 85:176–177.PubMed
- Suvajdzic N, Milenkovic B, Perunicic M, Stojsic J, Jankovic S: Two cases of sarcoidosis-lymphoma syndrome. Med Oncol 2007, 24:469–471.PubMedView Article
- Suen JS, Forse MS, Hyland RH, Chan CK: The malignancy-sarcoidosis syndrome. Chest 1990, 98:1300–1302.PubMedView Article
- Kornacker M, Kraemer A, Leo E, Ho AD: Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin’s lymphoma: report of two cases. Ann Hematol 2002, 81:103–105.PubMedView Article
- Sybert A, Butler TP: Sarcoidosis following adjuvant high-dose methotrexate therapy for osteosarcoma. Arch Intern Med 1978, 138:488–489.PubMedView Article
- Warburg O, Posener K, Negelein E: Über den stoffwechsel der carcinomzelle. Biochem Z 1924, 152:309–344.
- Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978, 19:1154–1161.PubMed
- Love C, Thomas MB, Tronco GG, Palestro CJ: FDG PET of infection and inflammation. Radiographics 2005, 25:1357–1368.PubMedView Article
- Bae YA, Lee KS, Han J, Ko YH, Kim BT, Chung MJ, Kim TS: Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue. Chest 2008, 133:433–440.PubMedView Article
- Beal KP, Yeung HW, Yahalom J: FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005, 16:473–480.PubMedView Article
- Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O: Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 2009, 94:1581–1589.PubMedView Article
- Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, et al.: Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2013, . [Epub ahead of print]
- Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, Richeldi L: Sarcoidosis: challenging diagnostic aspects of an old disease. Am J Med 2012, 125:118–125.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.